Supplementation with omega-3 fish oil has no effect on bone mineral density in adults with knee osteoarthritis: a 2-year randomized controlled trial
- 931 Downloads
This study aimed to determine the effect of fish oil on bone mineral density (BMD). There were no differences in the 2-year BMD measures between high and low dose groups after adjusting for baseline BMD. This randomized controlled trial did not demonstrate any efficacy of omega-3 fatty acids on bone loss in adults.
The purpose of this study is to investigate whether supplementation with high dose omega-3 fish oil could have an impact on BMD.
In a multicentre, double-blind randomized controlled trial (RCT) (ACTRN 12607000415404), 202 Australian participants aged ≥40 with knee osteoarthritis (mean age, 61.0 ± 10.0 years; 49 % female) were randomized to receive either high dose (4.5 g eicosapentaenoic acid and docosahexaenoic acid daily) or low dose (0.45 g/day) omega-3 fish oil for 2 years. BMD was assessed at baseline and 2 years by dual energy X-ray absorptiometry.
In subjects with baseline and 2-year assessments, mean standardized BMD at baseline for low or high dose group was 1198 ± 198 and 1157 ± 169 mg/cm2, respectively, for the lumbar spine and was 1035 ± 165 and 1017 ± 174 mg/cm2, respectively, for the femoral neck. There were no differences in the 2-year BMD measures between high and low dose groups after adjusting for baseline BMD in the complete case regression analyses (lumbar spine 3.7, 95 % confidence interval (CI) −7.9 to 15.3 mg/cm2 and femoral neck −5.5, 95 % CI −14.9 to 3.9 mg/cm2). The findings did not change with additional adjustments of age, gender, study centre and uses of bone-related drugs during the study period as well as using the intention-to-treat analysis or limiting to older participants (≥55 years at the baseline) (all P ≥ 0.25). Mild adverse events such as headache and gastrointestinal intolerance were common but did not occur more frequently in either group. There were no serious adverse events related to the intervention.
A 2-year supplementation with high-dose omega-3 fish oil did not alter bone loss among men and women with knee osteoarthritis.
KeywordsBone mineral density Docosahexaenoic acid Eicosapentaenoic acid Omega-3 fatty acids Randomized controlled trial
JS Chen was supported by the University of Sydney Rolf-Edgar Lake postdoctoral fellowship. He passed away in October 2014.
This study was funded by the Australian National Health and Medical Research Council Project Grant (451900) and a research grant from Arthritis Australia.
Compliance with ethical standards
All participants provided written consent. The study was approved by The Queen Elizabeth Hospital, Royal North Shore Hospital and Tasmanian Human Research Ethics Committees. The trial is registered with the Australian New Zealand Clinical Trials Registry (ACTRN 12607000415404)
Conflicts of interest
- 4.Heart Foundation (2015) Position statement fish, fish oils, n-3 polyunsaturated fatty acids and cardiovascular healthGoogle Scholar
- 6.Proudman SM, James MJ, Spargo LD, Metcalf RG, Sullivan TR, Rischmueller M, Flabouris K, Wechalekar MD, Lee AT, Cleland LG (2015) Fish oil in recent onset rheumatoid arthritis: a randomised, double-blind controlled trial within algorithm-based drug use. Ann Rheum Dis 74(1):89–95. doi: 10.1136/annrheumdis-2013-204145 CrossRefPubMedGoogle Scholar
- 11.Kruger MC, Coetzer H, de Winter R, Gericke G, van Papendorp DH (1998) Calcium, gamma-linolenic acid and eicosapentaenoic acid supplementation in senile osteoporosis. Aging (Milano) 10(5):385–394Google Scholar
- 14.Mangano K, Kerstetter J, Kenny A, Insogna K, Walsh SJ (2014) An investigation of the association between omega 3 FA and bone mineral density among older adults: results from the national health and nutrition examination survey years 2005–2008. Osteoporos Int 25(3):1033–1041. doi: 10.1007/s00198-013-2501-8 CrossRefPubMedPubMedCentralGoogle Scholar
- 17.Wu CW, Morrell MR, Heinze E, Concoff AL, Wollaston SJ, Arnold EL, Singh R, Charles C, Skovrun ML, FitzGerald JD, Moreland LW, Kalunian KC (2005) Validation of American College of Rheumatology classification criteria for knee osteoarthritis using arthroscopically defined cartilage damage scores. Semin Arthritis Rheum 35(3):197–201. doi: 10.1016/j.semarthrit.2005.06.002 CrossRefPubMedGoogle Scholar
- 20.Introduction to SAS. UCLA: Statistical Consulting Group. (accessed November 18, 2013) 2013Google Scholar
- 21.The U.S. Food and Drug Administartion (2005) Letter regarding dietary supplement health claim for omega-3 fatty acids and coronary heart diseaseGoogle Scholar
- 24.DeCaterina R, Giannessi D, Mazzone A, Bernini W, Lazzerini G, Maffei S, Cerri M, Salvatore L, Weksler B (1990) Vascular prostacyclin is increased in patients ingesting omega-3 polyunsaturated fatty acids before coronary artery bypass graft surgery. Circulation 82(2):428–438CrossRefPubMedGoogle Scholar
- 27.Watson PD, Joy PS, Nkonde C, Hessen SE, Karalis DG (2009) Comparison of bleeding complications with omega-3 fatty acids + aspirin + clopidogrel—versus—aspirin + clopidogrel in patients with cardiovascular disease. Am J Cardiol 104(8):1052–1054. doi: 10.1016/j.amjcard.2009.05.055 CrossRefPubMedGoogle Scholar